-
1
-
-
0038162585
-
Decline in the AIDS and death rates in the EuroSIDA study: An observational study
-
Mocroft A, Ledergerber B, Katlama C, et al. Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet. 2003;362:22-29.
-
(2003)
Lancet
, vol.362
, pp. 22-29
-
-
Mocroft, A.1
Ledergerber, B.2
Katlama, C.3
-
2
-
-
2642709177
-
Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators
-
Palella FJ Jr., Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998;338:853-860.
-
(1998)
N Engl J Med
, vol.338
, pp. 853-860
-
-
Palella Jr., F.J.1
Delaney, K.M.2
Moorman, A.C.3
-
4
-
-
33747122666
-
Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel
-
Hammer SM, Saag MS, Schechter M, et al. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel. JAMA. 2006;296:827-843.
-
(2006)
JAMA
, vol.296
, pp. 827-843
-
-
Hammer, S.M.1
Saag, M.S.2
Schechter, M.3
-
5
-
-
0037317499
-
Non-nucleoside reverse transcriptase inhibitors-an overview. Inf J
-
Bell C, Matthews GV, Nelson MR. Non-nucleoside reverse transcriptase inhibitors-an overview. Inf J SID AIDS. 2003:14:71-77.
-
(2003)
SID AIDS
, vol.14
, pp. 71-77
-
-
Bell, C.1
Matthews, G.V.2
Nelson, M.R.3
-
6
-
-
28144452516
-
Impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals
-
Clifford DB, Evans S, Yang Y, et al. Impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals. Ann Intern Med. 2005;143:714-721.
-
(2005)
Ann Intern Med
, vol.143
, pp. 714-721
-
-
Clifford, D.B.1
Evans, S.2
Yang, Y.3
-
7
-
-
0037192573
-
Determinants of recurrent toxicity-driven switches of highly active antiretroviral therapy. The ATHENA cohort
-
Dieleman JP, Jambroes M, Gyssens IC, et al. Determinants of recurrent toxicity-driven switches of highly active antiretroviral therapy. The ATHENA cohort. AIDS. 2002;16:737-745.
-
(2002)
AIDS
, vol.16
, pp. 737-745
-
-
Dieleman, J.P.1
Jambroes, M.2
Gyssens, I.C.3
-
8
-
-
0345256371
-
Patterns and correlates of discontinuation of the initial HAART regimen in an urban outpatient cohort
-
O'Brien ME, Clark RA, Besch CL, et al. Patterns and correlates of discontinuation of the initial HAART regimen in an urban outpatient cohort. J Acquir Immune Defic Syndr. 2003;34:407-414.
-
(2003)
J Acquir Immune Defic Syndr
, vol.34
, pp. 407-414
-
-
O'Brien, M.E.1
Clark, R.A.2
Besch, C.L.3
-
9
-
-
0242529051
-
-
d'Arminio Monforte A, Lepri AC, Rezza G, et al. Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naive patients. I.CO.N.A. Study Group. Italian Cohort of Antiretroviral-Naive Patients. AIDS. 2000; 14:499-507.
-
d'Arminio Monforte A, Lepri AC, Rezza G, et al. Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naive patients. I.CO.N.A. Study Group. Italian Cohort of Antiretroviral-Naive Patients. AIDS. 2000; 14:499-507.
-
-
-
-
10
-
-
0032701801
-
Analysis of the discontinuation of protease inhibitor therapy in routine clinical practice
-
Ferrer E. Consiglio E. Podzamczer D, et al. Analysis of the discontinuation of protease inhibitor therapy in routine clinical practice. Scand J Infect Dis. 1999;31:495-499.
-
(1999)
Scand J Infect Dis
, vol.31
, pp. 495-499
-
-
Ferrer, E.1
Consiglio, E.2
Podzamczer, D.3
-
11
-
-
0034960836
-
Predictors of protease inhibitor- associated adverse events
-
Bonfanti P, Ricci E, Landonio S, et al. Predictors of protease inhibitor- associated adverse events. Biomed Pharmacother. 2001 ;55:321 -323.
-
(2001)
Biomed Pharmacother
, vol.55
, pp. 321-323
-
-
Bonfanti, P.1
Ricci, E.2
Landonio, S.3
-
12
-
-
12944265462
-
-
Bonfanti P, Valsecchi L, Parazzini F, et al. Incidence of adverse reactions in HIV patients treated with protease inhibitors: a cohort study. Coordinamento Italiano Studio Allergia e Infezione da HIV (CISAI) Group. J Acquir Immune Defic Syndr. 2000;p23:236-245.
-
Bonfanti P, Valsecchi L, Parazzini F, et al. Incidence of adverse reactions in HIV patients treated with protease inhibitors: a cohort study. Coordinamento Italiano Studio Allergia e Infezione da HIV (CISAI) Group. J Acquir Immune Defic Syndr. 2000;p23:236-245.
-
-
-
-
13
-
-
0141923764
-
-
Murri R, Lepri AC, Phillips AN, et al. Access to antiretroviral treatment, incidence of sustained therapy interruptions, and risk of clinical events according to sex: evidence from the I.Co.N.A. Study. J Acquir Immune Defic Syndr. 2003;34:184-190.
-
Murri R, Lepri AC, Phillips AN, et al. Access to antiretroviral treatment, incidence of sustained therapy interruptions, and risk of clinical events according to sex: evidence from the I.Co.N.A. Study. J Acquir Immune Defic Syndr. 2003;34:184-190.
-
-
-
-
14
-
-
3142676567
-
Factors associated with efavirenz discontinuation in a large community-based sample of patients
-
Spire B, Carrieri P, Garzot MA, et al. Factors associated with efavirenz discontinuation in a large community-based sample of patients. AIDS Care. 2004;16:558-564.
-
(2004)
AIDS Care
, vol.16
, pp. 558-564
-
-
Spire, B.1
Carrieri, P.2
Garzot, M.A.3
-
15
-
-
3042716048
-
The pharmacogenetics of antiretroviral therapy: A review of studies to date
-
Quirk E, McLeod H, Powderiy W. The pharmacogenetics of antiretroviral therapy: a review of studies to date. Clin Infect Dis. 2004;39:98-106.
-
(2004)
Clin Infect Dis
, vol.39
, pp. 98-106
-
-
Quirk, E.1
McLeod, H.2
Powderiy, W.3
-
16
-
-
19944428456
-
Pharmacogenetics of efavirenz and central nervous system side effects: An Adult AIDS Clinical Trials Group study
-
Haos DW, Ribaudo HJ, Kim RB, et al. Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study. AIDS. 2004:18:2391-2400.
-
(2004)
AIDS
, vol.18
, pp. 2391-2400
-
-
Haos, D.W.1
Ribaudo, H.J.2
Kim, R.B.3
-
17
-
-
17644414659
-
Influence of 516G>T polymorphisms at the gene encoding the CYP450-2B6 isoenzyme on efavirenz plasma concentrations in HIV-infected subjects
-
Rodriguez-Novoa S, Barreiro P, Rendon A, et al. Influence of 516G>T polymorphisms at the gene encoding the CYP450-2B6 isoenzyme on efavirenz plasma concentrations in HIV-infected subjects. Clin Infect Dis. 2005:40:1358-1361.
-
(2005)
Clin Infect Dis
, vol.40
, pp. 1358-1361
-
-
Rodriguez-Novoa, S.1
Barreiro, P.2
Rendon, A.3
-
18
-
-
20244364148
-
Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients
-
Rofger M, Colombo S, Furrer H, et al. Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients. Pharmacogenet Genomics. 2005;15:1-5.
-
(2005)
Pharmacogenet Genomics
, vol.15
, pp. 1-5
-
-
Rofger, M.1
Colombo, S.2
Furrer, H.3
-
19
-
-
2942551228
-
Homozygous CYP2B6*6 (Ql 72H and K262R) correlates with high plasma efavirenz concentrations in HIV-l patients treated with standard efavirenz-containing regimens
-
Tsuchiya K, Gatanaga H, Tachikawa N, et al. Homozygous CYP2B6*6 (Ql 72H and K262R) correlates with high plasma efavirenz concentrations in HIV-l patients treated with standard efavirenz-containing regimens. Bio- chem Biophys Res Commun. 2004;319:1322-1326.
-
(2004)
Bio- chem Biophys Res Commun
, vol.319
, pp. 1322-1326
-
-
Tsuchiya, K.1
Gatanaga, H.2
Tachikawa, N.3
-
20
-
-
0035808574
-
Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1- infected patients
-
Marzolini C, Telenti A, Decosterd LA, et al. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1- infected patients. AIDS. 2001; 15:71-75.
-
(2001)
AIDS
, vol.15
, pp. 71-75
-
-
Marzolini, C.1
Telenti, A.2
Decosterd, L.A.3
-
21
-
-
0032727054
-
Characterization of the In Vitro Biotransformation of the HIV-l Reverse Transcriptase Inhibitor Nevirapine by Human Hepatic Cytochromes P-450
-
Erickson DA, Mather G, Trager WF, et al. Characterization of the In Vitro Biotransformation of the HIV-l Reverse Transcriptase Inhibitor Nevirapine by Human Hepatic Cytochromes P-450. Drug Mefab Dispos. 1999:27:1488-1495.
-
(1999)
Drug Mefab Dispos
, vol.27
, pp. 1488-1495
-
-
Erickson, D.A.1
Mather, G.2
Trager, W.F.3
-
22
-
-
33748328070
-
Pharmacogenetics of nevi- rapine-associated hepatotoxicity: An Adult AIDS Clinical Trials Group collaboration
-
Haas DW, Bartlett JA, Andersen JW, et al. Pharmacogenetics of nevi- rapine-associated hepatotoxicity: an Adult AIDS Clinical Trials Group collaboration. Clin Infect Dis. 2006;43:783-786.
-
(2006)
Clin Infect Dis
, vol.43
, pp. 783-786
-
-
Haas, D.W.1
Bartlett, J.A.2
Andersen, J.W.3
-
23
-
-
33748288115
-
Drug transporter and metabolizing enzyme gene variants and nonnucleoside reverse-transcriptase inhibitor hepatotoxicity
-
Ritchie MD, Haas DW, Motsinger AA, et al. Drug transporter and metabolizing enzyme gene variants and nonnucleoside reverse-transcriptase inhibitor hepatotoxicity. Clin Infect Dis. 2006;43:779-782.
-
(2006)
Clin Infect Dis
, vol.43
, pp. 779-782
-
-
Ritchie, M.D.1
Haas, D.W.2
Motsinger, A.A.3
-
24
-
-
85031348215
-
-
Moore RD, Keruly J, Gebo KA, et al. Racial Differences in Efavirenz Discontinuation in Clinical Practice. Paper presented at: 12th Conference on Retroviruses and Opportunistic Infections; February 22-25, 2005. Boston, MA.
-
Moore RD, Keruly J, Gebo KA, et al. Racial Differences in Efavirenz Discontinuation in Clinical Practice. Paper presented at: 12th Conference on Retroviruses and Opportunistic Infections; February 22-25, 2005. Boston, MA.
-
-
-
-
25
-
-
10044283687
-
Racial differences in clinical efficacy of efavirenz-based antiretroviral therapy
-
Paper presented at: February 24-28, Seattle, WA
-
Wegner S, Vahey M, Dolan M, et al. Racial differences in clinical efficacy of efavirenz-based antiretroviral therapy. Paper presented at: 9th Conference on Retroviruses and Opportunistic Infections; February 24-28, 2002. Seattle, WA.
-
(2002)
9th Conference on Retroviruses and Opportunistic Infections
-
-
Wegner, S.1
Vahey, M.2
Dolan, M.3
-
27
-
-
33747102040
-
Three- vs Four-Drug Antiretroviral Regimens for the Initial Treatment of HIV-l Infection: A Randomized Controlled Trial
-
Gulick RM, Ribaudo HJ, Shikuma CM, et al. Three- vs Four-Drug Antiretroviral Regimens for the Initial Treatment of HIV-l Infection: A Randomized Controlled Trial. JAMA. 2006:296:769-781.
-
(2006)
JAMA
, vol.296
, pp. 769-781
-
-
Gulick, R.M.1
Ribaudo, H.J.2
Shikuma, C.M.3
-
28
-
-
36549085175
-
Racial differences in virologic failure associated with adherence and quality of life on efavirenz- containing regimens for initial HIV therapy: Results of ACTG A5095
-
Schackman BR, Ribaudo HJ, Krambrink A, et al. Racial differences in virologic failure associated with adherence and quality of life on efavirenz- containing regimens for initial HIV therapy: results of ACTG A5095. J Acquir Immune Defic Syndr. 2007;46:547-554.
-
(2007)
J Acquir Immune Defic Syndr
, vol.46
, pp. 547-554
-
-
Schackman, B.R.1
Ribaudo, H.J.2
Krambrink, A.3
-
29
-
-
0036156409
-
Pharmacokinetic variability caused by gender: Do women have higher indinavir exposure than men?
-
Burger DM, Siebers MC, Hugen PW, et al. Pharmacokinetic variability caused by gender: do women have higher indinavir exposure than men? J Acquir Immune Defic Syndr. 2002;29:101-102.
-
(2002)
J Acquir Immune Defic Syndr
, vol.29
, pp. 101-102
-
-
Burger, D.M.1
Siebers, M.C.2
Hugen, P.W.3
-
30
-
-
2342563028
-
Sex-related differences in the pharmacokinetics of once-daily saquinavir soft-gelatin capsules boosted with low-dose ritonavir in patients infected with human immunodeficiency virus type 1
-
Pai MP, Schriever CA, Diaz-Linares M. et al. Sex-related differences in the pharmacokinetics of once-daily saquinavir soft-gelatin capsules boosted with low-dose ritonavir in patients infected with human immunodeficiency virus type 1. Pharmacotherapy. 2004;24:592-599.
-
(2004)
Pharmacotherapy
, vol.24
, pp. 592-599
-
-
Pai, M.P.1
Schriever, C.A.2
Diaz-Linares, M.3
-
31
-
-
7244243920
-
Steady-state pharmacokinetics of a double-boosting regimen of saquinavir soft gel plus lopinavir plus minidose ritonavir in human immunodeficiency virus-infected adults
-
Ribera E, Lopez RM, Diaz M, et al. Steady-state pharmacokinetics of a double-boosting regimen of saquinavir soft gel plus lopinavir plus minidose ritonavir in human immunodeficiency virus-infected adults. Antimicrob Agents Chemother. 2004;48:4256-4262.
-
(2004)
Antimicrob Agents Chemother
, vol.48
, pp. 4256-4262
-
-
Ribera, E.1
Lopez, R.M.2
Diaz, M.3
-
32
-
-
0742304500
-
Sex differences in nevirapine disposition in HIV-infected patients
-
Regazzi M, Villani P, Seminari E, et al. Sex differences in nevirapine disposition in HIV-infected patients. AIDS. 2003;17:2399-2400.
-
(2003)
AIDS
, vol.17
, pp. 2399-2400
-
-
Regazzi, M.1
Villani, P.2
Seminari, E.3
-
33
-
-
4043062089
-
No relationship between high nevirapine plasma concentration and hepatotoxicity in HIV-1-infected patients naive of antiretroviral treatment or switched from protease inhibitors
-
Dailly E, Billaud E, Reliquet V, et al. No relationship between high nevirapine plasma concentration and hepatotoxicity in HIV-1-infected patients naive of antiretroviral treatment or switched from protease inhibitors. Eur J Clin Pharmacol. 2004;60:343-348.
-
(2004)
Eur J Clin Pharmacol
, vol.60
, pp. 343-348
-
-
Dailly, E.1
Billaud, E.2
Reliquet, V.3
-
34
-
-
0036421181
-
Hepatotoxicity following nevirapine-containing regimens in HIV-l-infected individuals
-
De Maat MM, Mathot RA, Veldkamp Al, et al. Hepatotoxicity following nevirapine-containing regimens in HIV-l-infected individuals. Pharmacol Res. 2002:46:295-300.
-
(2002)
Pharmacol Res
, vol.46
, pp. 295-300
-
-
De Maat, M.M.1
Mathot, R.A.2
Veldkamp, A.3
-
35
-
-
14744297565
-
Interruption and discontinuation of highly active antiretroviral therapy in the multicenter AIDS cohort study
-
Li X, Margolick JB, Conover CS, et al. Interruption and discontinuation of highly active antiretroviral therapy in the multicenter AIDS cohort study. J Acquir Immune Defic Syndr. 2005;38:320-328.
-
(2005)
J Acquir Immune Defic Syndr
, vol.38
, pp. 320-328
-
-
Li, X.1
Margolick, J.B.2
Conover, C.S.3
-
36
-
-
0025690750
-
Use of automated databases for pharmacoepidemiology research
-
Strom BL, Carson JL. Use of automated databases for pharmacoepidemiology research. Epidemiol Rev. 1990;12:87-107.
-
(1990)
Epidemiol Rev
, vol.12
, pp. 87-107
-
-
Strom, B.L.1
Carson, J.L.2
-
37
-
-
0017274715
-
Medicaid records as a valid data source: The Tennessee experience
-
Federspiel CF, Ray WA, Schaffner W. Medicaid records as a valid data source: the Tennessee experience. Med Care. 1976; 14:166-172.
-
(1976)
Med Care
, vol.14
, pp. 166-172
-
-
Federspiel, C.F.1
Ray, W.A.2
Schaffner, W.3
-
38
-
-
0028800261
-
Recall accuracy for prescription medications: Self-report compared with database information
-
West SL, Savitz DA, Koch G, et al. Recall accuracy for prescription medications: self-report compared with database information. Am J Epidemiol. 1995,142:1103-1112.
-
(1995)
Am J Epidemiol
, vol.142
, pp. 1103-1112
-
-
West, S.L.1
Savitz, D.A.2
Koch, G.3
-
39
-
-
20744442305
-
Predictive factors of lopinavir/ritonavir discontinuation for drug-related toxicity: Results from a cohort of 416 multi-experienced HIV-infected individuals
-
Bongiovanni M, Cicconi P, Landonio S, et al. Predictive factors of lopinavir/ritonavir discontinuation for drug-related toxicity: results from a cohort of 416 multi-experienced HIV-infected individuals. Int J Antimicrob Agents. 2005;26:88-91.
-
(2005)
Int J Antimicrob Agents
, vol.26
, pp. 88-91
-
-
Bongiovanni, M.1
Cicconi, P.2
Landonio, S.3
-
40
-
-
0023680423
-
Nonsteroidal anti-inflammatory drug use and death from peptic ulcer in elderly persons
-
Griffin MR, Ray WA, Schaffner W. Nonsteroidal anti-inflammatory drug use and death from peptic ulcer in elderly persons. Ann Intern Med. 1988:109:359-363.
-
(1988)
Ann Intern Med
, vol.109
, pp. 359-363
-
-
Griffin, M.R.1
Ray, W.A.2
Schaffner, W.3
-
41
-
-
19244365446
-
Oral erythromycin and the risk of sudden death from cardiac causes
-
Ray WA, Murray KT, Meredith S, et al. Oral erythromycin and the risk of sudden death from cardiac causes. N Engl J Med. 2004;351:1089-1096.
-
(2004)
N Engl J Med
, vol.351
, pp. 1089-1096
-
-
Ray, W.A.1
Murray, K.T.2
Meredith, S.3
-
42
-
-
0037027050
-
COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease
-
Ray WA, Stein CM, Dougherty JR, et al. COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease. Lancet. 2002;360:1071-1073.
-
(2002)
Lancet
, vol.360
, pp. 1071-1073
-
-
Ray, W.A.1
Stein, C.M.2
Dougherty, J.R.3
-
43
-
-
14744291275
-
Prescribing of contraindicated protease inhibitor and statin combinations among HIV-infected persons
-
Hulgan T, Sterling TR, Daugherty J, et al. Prescribing of contraindicated protease inhibitor and statin combinations among HIV-infected persons. J Acquir Immune Defic Syndr. 2005;38:277-282.
-
(2005)
J Acquir Immune Defic Syndr
, vol.38
, pp. 277-282
-
-
Hulgan, T.1
Sterling, T.R.2
Daugherty, J.3
-
44
-
-
85031360889
-
-
Bailey J, Jenkins PH, Arheart KL, et al. The Impact of the Ryan White CARE Act on Quality and Outcomes of HIV/AIDS Care in Tennesee's TennCare System 1998-2000: Infectious Diseases Society of America; 2003.
-
Bailey J, Jenkins PH, Arheart KL, et al. The Impact of the Ryan White CARE Act on Quality and Outcomes of HIV/AIDS Care in Tennesee's TennCare System 1998-2000: Infectious Diseases Society of America; 2003.
-
-
-
-
45
-
-
0141955990
-
Improvements in access to care for HIV and AIDS in a statewide Medicaid managed care system
-
Bailey JE, Van Brunt DL, Raffanti SP, et al. Improvements in access to care for HIV and AIDS in a statewide Medicaid managed care system. Am J Manag Care. 2003;9:595-602.
-
(2003)
Am J Manag Care
, vol.9
, pp. 595-602
-
-
Bailey, J.E.1
Van Brunt, D.L.2
Raffanti, S.P.3
|